---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-025912"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2022-12-01T23:59:59+00:00"
generated_at: "2026-06-21T11:03:10.213983+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA clears Pyxis Oncology INDs for PYX-201 ADC and PYX-106 immunotherapy

## Summary
- FDA cleared IND for PYX-201, an ADC targeting tumor microenvironment for breast, head/neck, lung, thyroid cancers.
- FDA cleared IND for PYX-106, an immunotherapy targeting Siglec-15 for bladder, cholangiocarcinoma, colorectal, kidney cancers.
- Phase 1 trials planned to start in early 2023; cash runway extended into first half 2025.
- Pyxis Oncology transitions to clinical-stage company with veteran leadership team.

## SEC filing metadata
- accession: 0000950170-22-025912
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2022-12-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017022025912/0000950170-22-025912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017022025912/pyxs-20221201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-025912
- JSON: https://secwatch.observer/filing/0000950170-22-025912.json
- Plain text: https://secwatch.observer/filing/0000950170-22-025912.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.